pegylated interferon alfa
information and resources from the National Cancer Institute
NCI Thesaurus | pegylated interferon alfa
A covalent conjugate of recombinant interferon alpha and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha protein moiety. Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha, thereby extending the duration of its therapeutic effects, but may also reduce interferon-mediated stimulation of an immune response. NCI Thesaurus | pegylated interferon alfa
A covalent conjugate of recombinant interferon alpha and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha protein moiety. Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha, thereby extending the duration of its therapeutic effects, but may also reduce interferon-mediated stimulation of an immune response.
|
|
|
|
news articles
Gastroenterology issues probed 01 Apr 2006
Trade Arabia, ...virus. PEGASYS, (pegylated interferon alfa-2a), is the most frequently prescribed pegylated interferon for patients with hepatitis C. ...
Idenix Provides Update on Clinical Development of Valopicitabine ... Mar 23, 2006
PR Newswire (press release), ...randomized treatment arms, all involving dosing regimens of valopicitabine, administered once-daily, in combination with pegylated interferon alfa-2a (Pegasys(R ...
Idenix Provides Update on Clinical Development of Valopicitabine ... Mar 23, 2006
PR Newswire (press release), ...patients was designed to evaluate three dosing regimens of valopicitabine, administered once-daily, in combination with pegylated interferon alfa-2a (Pegasys(R ...
Idenix Announces Thirteen Data Presentations at the 2006 European ... Mar 17, 2006
PR Newswire (press release), Dr. Xiao-Jian Zhou, Idenix's Associate Director, Clinical Pharmacology, will present "Absence of Effect of Pegylated Interferon Alfa-2b on the Pharmacokinetics ...
HCV Data Drop HGS’ Shares; ‘Not Slam-Dunk,’ Analyst Says Mar 14, 2006
BioWorld Online (subscription), ...interferon alpha 2b), given every other week, at 12 weeks worked as well as the standard of care, which is weekly Pegasys (pegylated interferon alfa-2a) from F ...
Partial 24-Week Data Demonstrate Valopicitabine (NM283) Combined ... Dec 14, 2005
PR Newswire (press release), In all three arms, valopicitabine is given in combination with pegylated interferon alfa-2a (Pegasys(R)) 180 5g with the initial dose of pegylated interferon ...
Clinical Trials Update: Dec. 20, 2005 Dec 20, 2005
Forbes The purpose of this study is to see how safe it is to take NM283 and pegylated interferon alfa together and to measure how well this drug combination works to ...
TODAY ON PHARMALIVE.COM Dec 14, 2005
PharmaLive.com (press release), In all three arms, valopicitabine is given in combination with pegylated interferon alfa-2a (Pegasys(R)) 180 µg with the initial dose of pegylated ...
Viramidine May Reduce Anemia Complications of Hepatitis C ... Dec 16, 2005
DG News ...[Presentation title: Hemoglobin Decline and Anemia During HCV Therapy with Pegylated Interferon Alfa-2a with Either Viramidine or Ribavirin. Abstract 108].
Livers Under Wrap: ASLD 2005 Nov 25, 2005
MedPage Today, Treatment with pegylated interferon alfa-2a alone or in combination with Rebetol (Copegus) produces durable SVR in patients treated for hepatitis C infection ...
|
|
